The NIH and BARDA are sponsoring a prize competition in which up to $20 million will be awarded to contestants who develop new innovative laboratory diagnostic tools that detect and distinguish antibiotic resistant bacteria.
The challenge, structured in three phases, reaches out to researchers and innovators from both public and private sectors, as well as those outside of biomedical disciplines. It seeks rapid, point-of-need in vitro diagnostic research and product development which, over time, could lead to the development of more sensitive, accurate, robust and cost-effective assay approaches and devices for clinical diagnosis. Phases include:
- Submission – Up to 20 proposals will receive up to $50,000 and eligibility for phase 2
- Delivery of Prototype and Analytical Data – Up to 10 semifinalists will receive up to $100,000 and eligibility for phase 3
- Performance testing in CLIA-Certified Laboratories – $18,000,000 or more will be split among a maximum of 3 awardees
Proposals are due at 11:59pm on January 9, 2017. For more information, see the Antimicrobial Resistance Diagnostic Challenge.